Perkins Coie Trust Co Decreases Holdings in Medtronic PLC $MDT

Perkins Coie Trust Co decreased its stake in Medtronic PLC (NYSE:MDT - Free Report) by 96.5% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 39,985 shares of the medical technology company's stock after selling 1,115,440 shares during the quarter. Perkins Coie Trust Co's holdings in Medtronic were worth $3,808,000 as of its most recent SEC filing.Medtronic Stock Finds Its Footing—Now It’s Gaining MomentumSeveral other hedge funds have also recently modified their holdings of MDT. Brighton Jones LLC lifted its position in shares of Medtronic by 1,368.0% in the fourth quarter. Brighton Jones LLC now owns 39,989 shares of the medical technology company's stock valued at $3,194,000 after acquiring an additional 37,265 shares in the last quarter. T. Rowe Price Investment Management Inc. purchased a new stake in shares of Medtronic during the first quarter worth approximately $286,000. Martingale Asset Management L P raised its stake in Medtronic by 674.9% in the 1st quarter. Martingale Asset Management L P now owns 37,762 shares of the medical technology company's stock valued at $3,393,000 after purchasing an additional 32,889 shares during the last quarter. Price T Rowe Associates Inc. MD raised its stake in Medtronic by 42.9% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 10,059,135 shares of the medical technology company's stock valued at $903,915,000 after purchasing an additional 3,017,849 shares during the last quarter. Finally, Summit Financial LLC lifted its holdings in Medtronic by 10.9% in the 1st quarter. Summit Financial LLC now owns 22,556 shares of the medical technology company's stock valued at $2,027,000 after purchasing an additional 2,226 shares in the last quarter. Institutional investors and hedge funds own 82.06% of the company's stock. Wall Street Analysts Forecast GrowthA number of equities research analysts have recently issued reports on the stock. Wall Street Zen raised shares of Medtronic from a "hold" rating to a "buy" rating in a report on Saturday. Cowen reaffirmed a "buy" rating on shares of Medtronic in a research note on Friday, November 14th. Truist Financial cut their price objective on shares of Medtronic from $110.00 to $107.00 and set a "hold" rating for the company in a report on Thursday. Citigroup boosted their target price on Medtronic from $101.00 to $112.00 and gave the stock a "buy" rating in a report on Tuesday, October 7th. Finally, Morgan Stanley upped their price target on Medtronic from $107.00 to $117.00 and gave the company an "overweight" rating in a research report on Wednesday, November 19th. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and twelve have assigned a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $109.94.MarketBeat Week in Review – 08/18 - 08/22Check Out Our Latest Report on MedtronicTrending Headlines about MedtronicHere are the key news stories impacting Medtronic this week: Positive Sentiment: Medtronic filed an S-1 to take its Diabetes unit, MiniMed, public — the preferred separation path is an IPO followed by a split-off. Management says the move is part of a planned separation aimed at creating two focused companies, which could unlock value and provide strategic clarity. Medtronic announces filing of IPO registration statement for Diabetes business, MiniMed Positive Sentiment: Regulatory and product progress: Medtronic (and peers) secured FDA nods for liquid embolic systems — a reminder the company continues to advance therapeutic devices that can support organic growth beyond the diabetes separation. Medtronic, J&J MedTech both get FDA nods for liquid embolic systems Neutral Sentiment: Ownership and structure details may limit immediate financial impact — media reports note Medtronic expects to retain majority voting control (reported at least ~80.1% of voting stock), suggesting the IPO could be more about strategic focus and value crystallization than a full divestiture. Medtronic Spin-Off MiniMed Files for IPO Neutral Sentiment: Analyst stances remain cautious: some firms (e.g., Robert W. Baird) are maintaining "hold" ratings, reflecting mixed near-term views even as the strategic move unfolds. Robert W. Baird Remains a Hold on Medtronic (MDT) Negative Sentiment: Price-target trim: Truist cut its MDT price target modestly (from $110 to $107) and kept a "hold" rating, a sign some analysts see limited near-term upside despite the strategic separation. This analyst action could cap momentum until clearer financials for MiniMed and separation mechanics are disclosed. Medtronic price target lowered to $107 from $110 at Truist Medtronic Stock PerformanceMedtronic: The Opportunity Gets Healthier for Income InvestorsNYSE:MDT opened at $98.63 on Friday. The company's 50-day moving average is $97.38 and its two-hundred day moving average is $93.35. Medtronic PLC has a 1-year low of $79.29 and a 1-year high of $106.33. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.42 and a quick ratio of 1.80. The firm has a market capitalization of $126.45 billion, a price-to-earnings ratio of 26.59, a PEG ratio of 2.59 and a beta of 0.71. Medtronic (NYSE:MDT - Get Free Report) last released its quarterly earnings results on Tuesday, November 18th. The medical technology company reported $1.36 EPS for the quarter, beating the consensus estimate of $1.31 by $0.05. Medtronic had a net margin of 13.71% and a return on equity of 14.86%. The firm had revenue of $8.96 billion for the quarter, compared to analyst estimates of $8.86 billion. During the same quarter in the previous year, the company earned $1.26 EPS. The business's revenue for the quarter was up 6.6% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Analysts forecast that Medtronic PLC will post 5.46 EPS for the current year. Medtronic Dividend AnnouncementThe firm also recently declared a quarterly dividend, which will be paid on Friday, January 16th. Stockholders of record on Friday, December 26th will be paid a $0.71 dividend. This represents a $2.84 annualized dividend and a dividend yield of 2.9%. The ex-dividend date of this dividend is Friday, December 26th. Medtronic's dividend payout ratio is 76.55%. Medtronic Company Profile (Free Report)Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets. Medtronic's offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).Featured ArticlesFive stocks we like better than MedtronicHow to Short Nasdaq: An Easy-to-Follow GuideNike Beats on Earnings But Struggles in China and Faces TariffsWhat is the Australian Securities Exchange (ASX) Is the AI Boom a Bubble? These 2 Dividend Stocks Say NoBuy P&G Now, Before It Sets A New All-Time High4 High-Potential ETFs for 2026: Small Caps, Space Stocks, and MoreWant to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic PLC (NYSE:MDT - Free Report).This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Medtronic Right Now?Before you consider Medtronic, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medtronic wasn't on the list.While Medtronic currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here